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S U M M A R Y
Objectives: This phase III placebo-controlled study evaluated the immunogenicity and safety of
MenACWY-CRM vaccination in healthy Korean adolescents and adults.
Methods: Serum bactericidal activity with human complement (hSBA) was measured before and
1 month after vaccination against all four meningococcal serogroups. The IgG concentration speciﬁc for
serogroup W capsular polysaccharide was measured in a subset of subjects in a post-hoc analysis.
Adverse reactions were monitored throughout the study.
Results: Four hundred and ﬁfty subjects were randomized 2:1 to receive MenACWY-CRM (N = 297) or a
saline placebo (N = 153). MenACWY-CRM induced a good immune response against all four serogroups,
with seroprotection rates (hSBA titers 8) of 79%, 99%, 98%, and 94% for serogroups A, C, W, and Y,
respectively. Seroresponse rates were high for serogroups A, C, and Y, i.e. 76%, 86%, and 69%, respectively;
the rate for serogroup W was 28%. MenACWY-CRM vaccine induced serum bactericidal antibodies
against all four serogroups in a majority of subjects regardless of their baseline hSBA titers. MenACWY-
CRM was generally well tolerated with most reactions being transient and mild to moderate in severity.
Conclusions: Findings of this ﬁrst study of a quadrivalent meningococcal polysaccharide conjugate
vaccine in Korean adults and adolescents demonstrated that a single dose of MenACWY-CRM was well
tolerated and immunogenic, as indicated by the percentages of subjects with hSBA titers 8 (79%, 99%,
98%, and 94% of subjects) and geometric mean titers (48, 231, 147, and 107) against serogroups A, C, W,
and Y, respectively, at 1 month post-vaccination.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Table 1
Strains used for measurement of anticapsular bactericidal responses of serogroups
A, C, W, and Y
Strain Target antigen Phenotype Clonal complex (ST)
240070 W W:NT:P1.18-1,3 22 (184)
C11 C C:16:P1.7-1,1 NA (345)
F8238 A A:4,21:P1.20,9 5 (5)
860800 Y Y:NT:P1.5 167 (29)
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Neisseria meningitidis (N. meningitidis) is a leading cause of
bacterial meningitis and sepsis worldwide, capable of causing
outbreaks and epidemics of invasive disease.1,2 Permanent
disability or death can occur within hours of symptom onset
and morbidity and mortality rates are high even among the
patients who receive early antibiotic treatment.3,4 Approximately
500 000 cases of meningococcal disease occur annually worldwide
with a case-fatality rate of 10%.5 Although the highest rates of
meningococcal disease are in infants <1 year of age, a second peak
occurs in adolescence.6,7
Based on antigenic differences in their capsular polysaccharide,
at least 12 immunologically distinct serogroups of N. meningitidis
have been identiﬁed.8 However, >90% of disease is caused by
serogroups A, B, C, W, and Y.9 Serogroups B, C and Y cause much of
the meningococcal disease in the USA, Europe, and Australia,
whereas serogroup A, C, and W disease is more common in Asia
and Africa.9,10
MenACWY-CRM (Menveo1; Novartis Vaccines and Diagnos-
tics), a quadrivalent polysaccharide–CRM197 conjugate vaccine
containing meningococcal serogroups A, C, W, and Y, has been
approved for licensure in more than 50 countries including the
USA11 (in individuals 2 months to 55 years of age) and those of the
European Union12 (in subjects 11 years and older).
Previous phase II and III clinical trials have demonstrated
MenACWY-CRM to be highly immunogenic and well tolerated in
infants,13,14 children,15 adolescents,16–18 and adults.18–20
In Korea, meningococcal disease is a notiﬁable disease. In a
recent report, 401 cases of bacterial meningitis were observed in
17 university hospitals in Korea between 1996 and 2005.
Streptococcus pneumoniae, Haemophilus inﬂuenzae type b, and N.
meningitidis were the major etiologic agents of bacterial meningitis
in Korean children >3 months of age. N. meningitidis was
responsible for 4.5% of all cases, with a case-fatality rate of
16.7%.21 At the time this study was conducted, there were no
vaccines licensed in Korea for the control of meningococcal
disease.
This study was designed to evaluate the immunogenicity and
safety of a single dose of MenACWY-CRM in healthy adolescents
and adults 11–55 years of age in Korea.
2. Materials and methods
2.1. Study design
This multicenter, observer-blind, placebo-controlled phase III
study was conducted at eight centers in Korea from December
2010 to March 2011 (ClinicalTrials.gov identiﬁer NCT01274897).
The study was undertaken in accordance with Good Clinical
Practice and the Declaration of Helsinki. The ethics review
committee of each participating center approved the protocol,
and written informed consent was obtained from every
participant, or legal guardians where appropriate, prior to
enrolment.
2.2. Study subjects
A total of 450 participants were randomized 2:1 to receive
one dose of MenACWY-CRM (N = 297) or saline placebo
(N = 153). Eligible study participants were healthy subjects of
either sex between 11 and 55 years of age. Subjects were
excluded if they had a history of a previous or suspected disease
caused by N. meningitidis or had received any meningococcal
vaccine, had a serious acute, chronic, or progressive disease,
were pregnant, or had received any vaccine within 14 days (forinactivated vaccines) or 28 days (for live vaccines) prior to
enrollment.
2.3. Vaccine
Each 0.5-mL dose of MenACWY-CRM was composed of 10 mg of
MenA oligosaccharide and 5 mg each of oligosaccharides from
MenC, MenW, and MenY conjugated to CRM197. The vaccine was
prepared by extemporaneous mixing of the lyophilized MenA
component with the liquid MenCWY component immediately
before intramuscular injection in the deltoid area of the non-
dominant arm. Each 0.5-mL dose of saline placebo contained
4.5 mg sodium chloride in water for injection.
2.4. Immunogenicity
Blood samples were obtained for immunogenicity testing on
Day 1 (pre-vaccination) and Day 29 (1 month post-vaccination).
2.5. Serum bactericidal assay
Functional bactericidal antibodies were measured in pre- and
post-vaccination serum (in the same assays) using human
complement (hSBA) in the laboratories of Novartis Vaccines
(Marburg, Germany), as described previously.14 The strains used
for measurement of anti-capsular bactericidal responses of
serogroups A, C, W, and Y are presented in Table 1.
2.6. ELISA
The antibody concentration speciﬁc to serogroup W capsular
polysaccharide was assessed by enzyme-linked immunosorbent
assay (ELISA) in pre- and post-vaccination serum samples from a
subset of subjects (MenACWY-CRM group, N = 50; placebo group,
N = 20) in a post-hoc analysis. ELISA testing was performed at the
Health Protection Agency, Manchester, UK, as described previous-
ly.22
2.7. Safety
The safety and tolerability of MenACWY-CRM was assessed in
all subjects. Solicited local and systemic reactions were self-
recorded on diary cards for 7 days post-vaccination. All medically
attended adverse events (AEs) or serious AEs (SAEs) were
monitored for 29 days post-vaccination.
2.8. Statistical analysis
The primary immunogenicity objective was to assess the
immunogenicity of MenACWY-CRM as measured by the seror-
esponse rate at 1 month post-vaccination (Day 29). A conditional
deﬁnition of seroresponse was used, in which seroresponse was
deﬁned as a post-vaccination hSBA titer 8 for subjects who were
seronegative at baseline (hSBA titers <4), whereas for subjects who
were seropositive at baseline (hSBA titers 4), seroresponse was
deﬁned as a 4-fold increase over baseline hSBA titer. The primary
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95% Clopper–Pearson conﬁdence interval (LL 95% CI) for the overall
seroresponse rate was 50% for all four serogroups.
Secondary objectives included immunogenicity assessment as
measured by hSBA geometric mean titers (GMTs) and by the
percentage of subjects with hSBA titers 8 at 1 month post-
vaccination, per serogroup. In a post-hoc analysis, antibodies
against serogroup W polysaccharide were measured by ELISA and
expressed as IgG antibody geometric mean concentrations (GMCs).
An IgG concentration 2.0 mg/mL was used as the cut-off. This
level has been proposed for serogroups A and C and thus was
applied in this analysis, although protection is not presumed since
the correlate has not been established for MenW.23–26 Pearson’s
correlation coefﬁcients were used to assess the relationship
between hSBA titers and concentration of antibodies determined
by ELISA.
Sample size calculations were based on previous Novartis
studies17,20 conducted in the same age group, in which seror-
esponse rates of 71%, 72%, 67%, and 64% were observed for
serogroups A, C, W, and Y, respectively. Assuming similar results,
the power to detect a seroresponse rate 50% given 240 evaluable
subjects would be 99% for each of the four serogroups, for an
overall power of 96%. GMTs were computed by exponentiating
(base 10) the least square means of the logarithmically trans-
formed (base 10) titers, and their 95% CIs were obtained from a
two-way analysis of variance with factors for vaccine group and
center. The percentage of subjects with hSBA titers 8 and
associated 95% CIs were computed for each vaccine group, using
normal approximation where appropriate. Safety data were
expressed as the number or percentage of subjects with AEs in
each group.
All statistical analyses were performed using SAS1 version 9.1
(SAS Institute, Cary, NC, USA).Figure 1. Participa3. Results
3.1. Subjects
A total of 450 healthy subjects were enrolled, 297 of whom
received a dose of MenACWY-CRM and 153 of whom received the
saline placebo (Figure 1). The mean age was 19.5 years
(MenACWY-CRM, 19.6 years (mean)  9.2 (standard deviation);
placebo, 19.3 years  8.9); all were of Asian origin and 52% were
male. Height (164 cm  10.0; 163.9 cm  8.9) and weight (58.0 kg 
12.7; 58.8 kg  12.9) were similar between the MenACWY-CRM and
placebo groups, respectively. All enrolled subjects completed the
study.
3.2. Immunogenicity
The immunogenicity analysis was based on the per-protocol
(PP) population, which included all subjects who received an
appropriately timed vaccine dose and provided appropriately
timed evaluable serum samples (MenACWY-CRM, N = 296; place-
bo, N = 152).
The majority of MenACWY-CRM group subjects achieved
seroresponse against serogroups A (76%), C (86%), and Y (69%),
while the rate for serogroup W was 28% (Figure 2). The LL 95% CIs
for these seroresponse rates were 71%, 82%, 23%, and 63% for
serogroups A, C, W, and Y, respectively. As the LL 95% CI for the
seroresponse rate against serogroup W was <50%, the primary
objective was not met.
Among MenACWY-CRM vaccine recipients who were sero-
negative at baseline, high seroresponse rates were achieved: 76%
(95% CI 70–81%) for serogroup A, 96% (95% CI 91–99%) for
serogroup C, 84% (95% CI 67–95) for serogroup W, and 89% (95% CI
82–94%) for serogroup Y. Comparatively few subjects werent ﬂow chart.
Figure 2. Seroresponse rates per serogroup and per vaccine group at 1 month post-
vaccination (Day 29): overall seroresponse rates and seroresponse rates in subsets
of subjects who were seronegative at baseline and seropositive at baseline. Overall
seroresponse: post-vaccination hSBA titers 8 for subjects who were seronegative
(hSBA titers <4) at baseline; 4-fold increase over pre-vaccination titers for
subjects who were seropositive (hSBA titers 4) at baseline. hSBA, serum
bactericidal activity assay using human complement.
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(MenACWY-CRM, 17%; placebo, 21%), but high percentages of
subjects were baseline seropositive for serogroups C (62%, 55%), W
(89%, 87%), and Y (60%, 59%) in the MenACWY-CRM and placebo
groups, respectively.
Baseline GMTs were comparable between the groups for
serogroups A (2.7, 2.9), C (7.8, 5.9), and Y (9.0, 8.8), respectively,
however the GMTs were higher against serogroup W (51, 48). In
the placebo group, GMTs did not differ signiﬁcantly between Days
1 and 29 for any serogroup. In contrast, an increase in GMTs was
observed in the MenACWY-CRM group at 29 days post-vaccina-
tion, with 18-, 29-, 2.9-, and 12-fold increases over baseline with
GMTs of 48, 231, 147, and 107 for serogroups A, C, W, and Y,
respectively (Figure 3A). The percentages of subjects with hSBA
titers 8 at baseline were relatively high for serogroups C (49%;
39%), W (89%; 87%), and Y (54%; 53%) and low for serogroup A (13%;
15%) in the MenACWY-CRM and placebo groups, respectively.
After MenACWY-CRM vaccination, these rates increased to 79%,99%, 98%, and 94% for serogroups A, C, W, and Y, respectively
(Figure 3B), but there was no increase for any serogroup in the
placebo group.
Responses to serogroup W at baseline and 1 month post-
vaccination are shown in the reverse cumulative distribution of
hSBA titers (Figure 4). The curve for the MenACWY-CRM group at
1 month post-vaccination is further to the right, illustrating a pre-
to post-vaccination increase in the MenACWY-CRM group but not
the placebo group.
In order to explore the speciﬁcity of bactericidal antibodies
against the serogroup W capsule, post-hoc testing of sera from
50 MenACWY-CRM subjects (40 baseline seropositive and
10 baseline seronegative) and 20 placebo group subjects (16 base-
line seropositive and four baseline seronegative) was performed by
serogroup W speciﬁc IgG ELISA. Pre-vaccination ELISA GMCs
against serogroup W capsule were 0.37 mg/mL and 0.14 mg/mL in
the MenACWY-CRM and placebo groups, respectively. One month
post-vaccination, GMCs against serogroup W had risen to 20 mg/
mL in the MenACWY-CRM group but remained low in the placebo
group (0.23 mg/mL) (Table 2). Using the 2.0 mg/mL cut-off, 94% of
MenACWY-CRM recipients and 0% of placebo group subjects
showed elevated responses at 1 month post-vaccination (Table 2).
Also, there was a negligible correlation (r = 0.19; p = 0.12) between
pre-vaccination hSBA titers and pre-vaccination serogroup W
polysaccharide-speciﬁc IgG concentrations (ELISA), whereas there
was a signiﬁcant post-vaccination correlation between hSBA titers
and IgG concentrations in MenACWY-CRM group subjects
(r = 0.52; p < 0.001).
3.3. Safety
All enrolled subjects (450) were included in the safety analysis.
MenACWY-CRM vaccination was generally well tolerated. The
percentage of subjects reporting solicited local reactions within
7 days of vaccination was higher in the MenACWY-CRM group
(28%) than in the placebo group (9%), whereas the percentage of
subjects reporting systemic reactions was similar in both groups
(28%). MenACWY-CRM vaccination was associated with more
reports of transient, mild to moderate injection site pain (23% vs.
8%) than placebo injections. The most common systemic reaction
was myalgia, reported by 15% and 8% in the MenACWY-CRM and
placebo groups, respectively, and none were severe. Fever (38 8C)
was reported by 1% of subjects in each group and none had a
temperature 40 8C (Table 3).
Unsolicited AEs during Days 1–29 were reported in 12% of
subjects in the MenACWY-CRM group and 7% in the placebo group;
4% of subjects in the MenACWY-CRM group and 1% in the placebo
group reported unsolicited AEs that were possibly or probably
related to vaccination. The most commonly reported AE was
injection site pruritus, reported by three subjects (1%) after
MenACWY-CRM vaccination. There were no SAEs, deaths, or
premature withdrawals reported during the study.
4. Discussion
This study was the ﬁrst evaluation of the immunogenicity and
tolerability of MenACWY-CRM in healthy Korean adolescents and
adults. MenACWY-CRM vaccination induced an immune response
against all four serogroups, as evidenced by the percentages of
subjects with hSBA titers 8 (79%, 99%, 98%, and 94% for
serogroups A, C, W, and Y, respectively) and increases in the ratio
of hSBA GMTs against the four serogroups (2.9- to 29-fold
increases). This immune response is similar to that measured in
subjects 11–55 years of age in two pivotal clinical studies used for
licensure in Europe and the rest of the world.17,20
Figure 3. (A) hSBA GMTs at baseline (Day 1) and at 1 month post-vaccination (Day 29), and (B) percentages of subjects with hSBA titers 8 at baseline and at 1 month post-
vaccination in the MenACWY-CRM and placebo groups. hSBA, serum bactericidal activity assay using human complement; GMT, geometric mean titer.
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in this study as contingent upon pre-vaccination hSBA titers: for
baseline seronegative subjects (hSBA titers <4), seroresponse was
deﬁned as post-vaccination hSBA titers 8, and for baseline
seropositive subjects (hSBA titers 4), as a 4-fold increase over
pre-vaccination titers. Seroresponse rates against serogroups A, C,
and Y (and associated LL 95% CIs) were somewhat higher in the
present study in comparison with the previous MenACWY-CRM
studies conducted in the same age range.17,20 However the
seroresponse rate for serogroup W was lower in the present
study; 28% of subjects achieved seroresponse for serogroup W at
1 month post-vaccination. Seroresponse is deﬁned by the pre-
vaccination antibody levels, and in this study, pre-vaccination
hSBA was particularly striking for serogroup W, with 88% of the
subjects baseline seropositive, much higher than in previous
studies. Focusing on those subjects who were baseline seronega-
tive for serogroup W, 84% achieved seroresponse for serogroup W
and the LL 95% CI was 67%, which would have satisﬁed the
predeﬁned criteria. Also, the percentage of subjects with hSBA
titers 8 for serogroup W at 1 month post-vaccination was
signiﬁcantly higher in MenACWY-CRM recipients than in the
placebo group (as evidenced by non-overlapping CIs) (Figure 2).Figure 4 clearly illustrates the immunogenicity of MenACWY-CRM
against the serogroup W strain despite the high baseline titers and
corresponding low seroresponse. Thus the observed levels of pre-
vaccination serogroup W hSBA titers in this study were analyzed
further for speciﬁcity and warrant further discussion.
The serum bactericidal assay measures cumulative killing of all
bactericidal antibodies in the vaccine recipient’s serum against the
test strain and is not speciﬁc for anti-capsular antibodies.
Therefore, bactericidal antibodies against other non-capsular
antigens contained in the outer membrane of any bacteria that
cross-react with any of the proteins on this W strain or cross-
reactive capsular polysaccharides could be responsible for the
measured pre-vaccination hSBA titers. Because ELISA measures
only anti-capsular polysaccharide antibodies, a comparison of
hSBA and ELISA results can help determine the extent to which
baseline hSBA titers reﬂect anti-capsular antibodies. We found a
weak, non-signiﬁcant correlation between serogroup W hSBA
titers and serogroup W ELISA IgG concentrations for pre-
vaccination samples (r = 0.19; p = 0.12). There was a signiﬁcant
correlation between hSBA titers and ELISA IgG concentrations in
post-vaccination samples of subjects vaccinated with MenACWY-
CRM (r = 0.52; p < 0.001). Similar correlations in post-vaccination
Figure 4. Reverse cumulative distribution of hSBA titers against serogroup W at
baseline (Day 1) and at 1 month post-vaccination (Day 29) in the MenACWY-CRM
group and placebo group. Day 1: MenACWY-CRM, blue squares; placebo, green
circles. Day 29: MenACWY-CRM, red triangles; placebo, purple diamonds; hSBA 1:8
for reference, black dashed line.
Table 3
Numbers (%) of subjects with local and systemic reactions during the 7 days after
vaccination
MenACWY-CRM
(N = 297)
Placebo
(N = 153)
Local reactions
Pain Any 69 (23) 12 (8)
Severe 0 0
Erythema (mm) Any 30 (10) 3 (2)
>100 mm 8 (3) 0
Induration (mm) Any 30 (10) 0
>100 mm 4 (1) 0
Systemic reactions
Chills Any 17 (6) 7 (5)
Severe 0 0
Nausea Any 22 (7) 10 (7)
Severe 1 (<1) 0
Myalgia Any 45 (15) 13 (8)
Severe 0 0
Arthralgia Any 6 (2) 4 (3)
Severe 0 0
Headache Any 39 (13) 25 (16)
Severe 1 (<1) 0
Rash Any 1 (<1) 0
Severe 0 0
Fever (38 8C) Yes 3 (1) 1 (1)
Other
Axillary temperature <38.0 8C 294 (99) 152 (99)
40 8C 0 0
Use of analgesic or antipyretic Yes 7 (2) 3 (2)
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correlation was found between serogroup C hSBA and serogroup C
ELISA antibody concentrations for pre-vaccination samples, but
signiﬁcant correlations were found in post-vaccination sera.
Further evidence of the speciﬁcity of the hSBA response to
MenACWY-CRM vaccine is illustrated in the analysis of the W
polysaccharide speciﬁc IgG GMCs. This data shows that pre-
vaccination GMCs measured against serogroup W were low in both
groups and GMCs increased between pre- and post-vaccination
only in the MenACWY-CRM group, not in the placebo group. We
used 2.0 mg/mL as the cut-off for analysis.23,24 However, this cut-
off was established in a Finnish efﬁcacy study, which proposed this
as a MenA correlate of protection. In that previous study, the
concentration was measured in a majority of vaccinated individu-
als for whom the serogroup A polysaccharide vaccine was shown to
be effective. No clear correlate of protection has been established
for MenW.
In the present study, 94% of MenACWY-CRM recipients had
putative protective levels of serogroup W IgG concentrations
(2 mg/mL) at 1 month post-vaccination and similar percentages
of subjects achieved this level regardless of whether they were
baseline hSBA seronegative (90% 2 mg/mL) or seropositive (95%
2 mg/mL). In contrast, none of the placebo group subjects had
serogroup W IgG concentrations 2.0 mg/mL at 1 month post-
vaccination.Table 2
Total IgG ELISA results against serogroup W, by pre-vaccination hSBA titer
Baseline
hSBA titer
Pre-vaccina
GMC (mg/m
MenACWY-CRM (N = 50) hSBA<1:4 (N = 10) 0.28 (0.13–
hSBA 1:4 (N = 40) 0.39 (0.26–
Overall 0.37 (0.26–
Placebo (N = 20) hSBA<1:4 (N = 4) 0.14 (0.04–
hSBA 1:4 (N = 16) 0.14 (0.031
Overall 0.14 (0.17–
hSBA, serum bactericidal activity with human complement; ELISA, enzyme-linked immTaken together, the serogroup W hSBA and ELISA results imply
that the bactericidal antibodies detected in pre-vaccination serum
samples were, for the most part, not speciﬁc to serogroup W
capsular polysaccharides. This highlights a limitation in the
conditional deﬁnition of seroresponse. The deﬁnition assumes
that pre-vaccination hSBA titers in subjects classiﬁed as baseline
seropositive are largely speciﬁc to serogroup W capsular poly-
saccharides. As this appears not to be the case, the majority of
subjects could more properly have been categorized as baseline
seronegative for the relevant anti-capsular antibodies induced by
the glycoconjugate vaccine. For seronegative subjects, serore-
sponse was deﬁned as a post-vaccination hSBA titer 8, and 98% of
MenACWY-CRM recipients had hSBA titers 8 against serogroup
W.
The causes of the high naturally acquired (pre-vaccination)
bactericidal antibodies in this population to serogroup W, as well
as serogroups C and Y, cannot be attributed to antibodies speciﬁc
for capsular polysaccharide antigens only. Antibody priming with
cross-reactive antigens such as subcapsular protein antigens can
occur during environmental exposure to Neisseria spp28 or certain
types of enteric bacteria.29 Additional analysis with other
serogroup W strains with different subcapsular antigens could
have provided additional bactericidal data to clarify the high
naturally acquired antibodies in this population, but was not
possible in this case.tion ELISA
L)
Post-vaccination
ELISA GMC (mg/mL)
Post-vaccination
% subjects with
2 mg/mL (95% CI)
0.62) 17 (6.69–45) 90% (55–100%)
0.59) 21 (13–34) 95% (83–99%)
0.52) 20 (13–31) 94% (83–99%)
0.5) 0.14 (0.031–0.62) 0% (0–60%)
–0.62) 0.26 (0.12–0.54) 0% (0–21%)
0.5) 0.23 (0.12–0.43) 0% (0–17%)
unosorbent assay; GMC, geometric mean concentration; CI, conﬁdence interval.
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was generally well tolerated and had an acceptable safety proﬁle.
Only transient or mild to moderate solicited local and systemic
reactions occurred. None of the subjects reported serious reactions.
Previous MenACWY-CRM studies have also shown MenACWY-
CRM to have an established safety proﬁle in children,15 adoles-
cents,16–18 and adults.18–20
In conclusion, this ﬁrst study of a quadrivalent meningococcal
polysaccharide conjugate vaccine in Korea demonstrates that a
single dose of MenACWY-CRM was well tolerated and immuno-
genic in Korean adolescents and adults, as demonstrated by the
percentages of subjects with hSBA titers 8 (79%, 99%, 98%,
and 94% of subjects) and GMTs (48, 231, 147, and 107) against
serogroups A, C, W, and Y, respectively, at 1 month post-
vaccination.
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